Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronika Auner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Opinion on Medical Diagnostics|March 19, 2013
New and potential clinical applications of KRAS as a cancer biomarkerGernot Kriegshäuser, Veronika Auner, Robert Zeillinger
Gynecologic Oncology|November 20, 2009
ABC transporter gene expression in benign and malignant ovarian tissueVeronika Auner, Jalid Sehouli, Gülten Oskay-Oezcelik, et al.
BMC Cancer|April 11, 2009
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assayVeronika Auner, Gernot Kriegshäuser, Dan Tong, et al.
Journal of Clinical Pathology|January 25, 2011
KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assayGernot Kriegshäuser, Veronika Auner, Eva Schuster, et al.
Cancer|October 26, 2012
Methylation status of TUSC3 is a prognostic factor in ovarian cancerDietmar Pils, Peter Horak, Petr Vanhara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Opinion on Medical Diagnostics|March 19, 2013
New and potential clinical applications of KRAS as a cancer biomarkerGernot Kriegshäuser, Veronika Auner, Robert Zeillinger
Gynecologic Oncology|November 20, 2009
ABC transporter gene expression in benign and malignant ovarian tissueVeronika Auner, Jalid Sehouli, Gülten Oskay-Oezcelik, et al.
BMC Cancer|April 11, 2009
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assayVeronika Auner, Gernot Kriegshäuser, Dan Tong, et al.
Journal of Clinical Pathology|January 25, 2011
KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assayGernot Kriegshäuser, Veronika Auner, Eva Schuster, et al.
Cancer|October 26, 2012
Methylation status of TUSC3 is a prognostic factor in ovarian cancerDietmar Pils, Peter Horak, Petr Vanhara, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
Pageof 1